AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's TitleInvestors Business Daily • 04/26/24
AbbVie's first-quarter results top expectations as arthritis drugs fuel growthMarket Watch • 04/26/24
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in studyReuters • 04/25/24
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 BuysSeeking Alpha • 04/25/24
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis StudyPRNewsWire • 04/25/24
Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 04/23/24
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest BrandsPRNewsWire • 04/23/24
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell ArteritisPRNewsWire • 04/18/24
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable TherapiesBusiness Wire • 04/16/24